S&P 500, Nasdaq Close at Record Highs After Fed Chair Powell's Comments
The S&P 500 and the Nasdaq Composite closed at record highs Tuesday after Federal Reserve Chair Jerome Powell said policymakers have made "quite a bit of progress" against inflation. The tech-heavy Na
Sector Update: Health Care Stocks Retreat Tuesday Afternoon
Health care stocks were declining Tuesday afternoon, with the NYSE Health Care Index shedding 0.8% and the Health Care Select Sector SPDR Fund (XLV) down 0.7%. The iShares Biotechnology ETF (IBB) fell
This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Incyte Drops as BMO Downgrades on $2B Buybacks
Today's Morning Movers and Top Ratings: PARA, CRWD, LEN, PYPL and More
CrowdStrike's stock decreased by 2.36% after Piper Sandler changed its rating on the cybersecurity company to "neutral" from "overweight," mentioning valuation concerns.
Express News | Incyte Shares Are Trading Lower After BMO Capital Downgraded the Stock From Market Perform to Underperform and Lowered Its Price Target From $52 to $48
Express News | Incyte Corp : BMO Cuts Target Price to $48 From $52
Express News | Incyte Corp : BMO Cuts to Underperform From Market Perform
Express News | Incyte Shares Down 3% Premarket; BMO Downgrades to "Underperform" From "Market Perform", as per Thefly.com
BMO Capital Downgrades Incyte(INCY.US) to Sell Rating, Cuts Target Price to $48
BMO Capital analyst Evan Seigerman downgrades $Incyte(INCY.US)$ to a sell rating, and adjusts the target price from $56 to $48.According to TipRanks data, the analyst has a success rate of 51.1% and a
Incyte Cut to Underperform From Market Perform by BMO Capital
Incyte Cut to Underperform From Market Perform by BMO Capital
Biggest Stock Movers Today: PARA, INCY, and More
Express News | BMO Capital Downgrades Incyte to Underperform, Lowers Price Target to $48
Daily short sale tracking: Rivian Automotive's short volume increased by 32 million, with a short sale ratio of 15%
Rivian Automotive(RIVN.US) ranked top of the list had the largest change in short volume (32.01 million shares), and the short volume ratio of Incyte(INCY.US) reached 43.97%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)
Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Market Report: Featuring Abeome, ABL Bio, Agenus, Akeso Biopharma, AnaptysBio, EpimAb Biotherapeutics, Immutep, Incyte and Y-Biologics
M&A Is Back. 4 Stocks That Could Be Targets.
Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.
Analyst Expectations For Incyte's Future
6 analysts have shared their evaluations of Incyte (NASDAQ:INCY) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recen
Express News | Cantor Fitzgerald Reiterates Neutral on Incyte
Incyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 — Cantor Fitzgerald Reiterates → Neutral 05/23/2024 -12.27% Deutsche Bank → $55 Initiates Cove
No Data